The role of gastric cancer patient-derived organoids in precision medicine: Clinicians’ perspective

Organoid technology holds great potential and hope for personalized treatment in gastric cancer (GC). To date, clinicians’ views on this technology for precision oncology have not been reported despite these insights being invaluable to understanding how organoids may be effectively integrated into clinical practice. Hence, we explored clinicians’ knowledge and perception of organoid research and its potential clinical utility in GC treatment. Clinicians believed that organoids would be most useful for guiding adjuvant treatment in patients who fail neoadjuvant therapy and emphasized the importance of obtaining results within 4–6 weeks of surgical resection. Clinicians also expressed concerns and suggestions related to current research methodologies and highlighted the ethical and political aspects of organoid-guided personalized medicine. Overall, most clinicians perceived the value in the use of organoids to guide personalized treatment in GC and provided important insights into how this approach could be best implemented in clinical practice in the future.